Loading
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (2 ops.)
Latest filing published 31 Jan 2024 for Kura Oncology, Inc., €72k. Read the official filing
Filing timeline
BuySaleStephen Dale
Insider track record
Disclosed buys
0
Disclosed sells
2
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Stephen Dale: trading record in brief
Stephen Dale (senior executive) discloses dealings in Kura Oncology, Inc. to SEC (Form 4). The record holds 4 filings, for trades running from 26 January 2022 to 29 January 2024.
Every open-market trade on record is a sale: 2 sales worth €128k. Other entries cover 2 share grants. So far in 2024, the count stands at no purchases and 1 sale.
The latest filing, published on 31 January 2024, reports an open-market sale of €72k in Kura Oncology, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 3 days. US insiders must file a Form 4 within two business days of a trade. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Companies and markets linked to Stephen Dale
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations4 total
4,400 shares@ US$17.800556.4% of flowCommon StockSEC:0000950170-24-009493:0
23,125 shares0Common StockSEC:0001209191-23-011283:0
4,385 shares@ US$13.890343.6% of flowCommon StockSEC:0001209191-23-005744:0
36,900 shares0Common StockSEC:0001209191-22-005367:0
4 of 4 declarations
